On February 8, 2022 Photocure ASA (OSE: PHO), The Bladder Cancer Company, reported that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl will present a corporate overview and host 1-on-1 meetings with investors at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually February 14-18, 2022 (Press release, PhotoCure, FEB 8, 2022, View Source [SID1234607869]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Photocure’s presentation is scheduled to take place February 17th at 11:20am ET (5:20pm CET) and can be accessed via the link below: View Source

On February 8, 2022 Applied Cells, a leading provider of cell preparation and isolation solutions for tumor biology research, reported a joint marketing agreement with S2 Genomics to further the field of tumor biology (Press release, Applied Cells, FEB 8, 2022, View Source [SID1234607868]). The joint program leverages S2 Genomics’ Proprietary Singulator 100 System for dissociation of solid tissue into cell and nuclei suspensions integrated with Applied Cells’ proprietary MARS Acoustics and Magnetic technologies to provide a complete workflow for tissue sample preparation. The automated Singulator gently processes a wide range of tissue types. Once dissociated, the MARS system provides a fast process for debris removal resulting in high purity, high recovery of single cells or nuclei for downstream analytics such as single cell sequencing, flow and image cytometry. The combined power of the platforms ensures fast, gentle processing of precious tissue samples that maintain healthy, non-exhausted cellular structures.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are committed to bringing a total solution approach to our customers," said Janette Phi, CCO of Applied Cells. "Our joint marketing with S2 Genomics provides a powerful combination of Singulator and MARS solutions to the field of tumor biology."

S2 Genomics is focused on facilitating scientific discovery by providing advanced tools and automated workflows to our customers. Generating highly purified suspensions of cells or nuclei is essential for obtaining high quality single cell genomics or flow cytometry data. We are excited to partner with Applied Cells to deliver superior workflow solutions to our customers.

On February 8, 2022 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, reported that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET (Press release, BeiGene, FEB 8, 2022, View Source;2022-Oncology-Conference [SID1234607867]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed from the investors section of BeiGene’s website at View Source or View Source An archived replay will be available for 90 days following the event.

On February 8, 2022 Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, reported that Michael Gilman, Ph.D., Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks Oncology Conference on Friday, February 11, 2022 at 10:00 a.m. ET (Press release, Arrakis Therapeutics, FEB 8, 2022, View Source [SID1234607866]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 8, 2022 EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, reported a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology (Press release, EdiGene, FEB 8, 2022, View Source [SID1234607865]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of our CRISPR discovery engine beyond our wholly-owned in vivo genetic medicine approaches for the benefit of even more patients," said Devyn Smith, Ph.D., Chief Executive Officer of Arbor. "We look forward to expanding the global impact of Arbor’s proprietary gene editing technologies through our partnership with EdiGene."

The licensed technology is a part of Arbor’s proprietary CRISPR gene-editing portfolio, which is tailored to address the underlying pathology of genetic diseases.

"It has been great working with Arbor’s team in the past year to optimize ways of integrating Arbor’s proprietary CRISPR system into our ex vivo platforms," said Dong Wei, Ph.D., CEO of EdiGene. "This partnership will expand EdiGene’s gene-editing toolkit and strengthen our capabilities to advance ongoing ex vivo gene-editing cell therapy programs for multiple serious diseases. We look forward to collaborating with Arbor to achieve our shared commitment to developing innovative therapies to address unmet medical needs."

Under the agreement, EdiGene will pay Arbor certain upfront, milestone payments, commercial payments upon the achievement of certain development and sales milestones, and tiered royalties on net sales of royalty-bearing EdiGene products.